HCFA ADMINISTRATOR ROPER SEES "TWO SIDES" TO PHYSICIAN DISPENSING
HCFA ADMINISTRATOR ROPER SEES "TWO SIDES" TO PHYSICIAN DISPENSING and issues involving physician-owned home I.V. administration businesses and clinical laboratories. Addressing a Sept. 16-19 meeting of the National Council of State Pharmaceutical Association Executives, hosted by the American Pharmaceutical Association in Washington, D.C., Roper said he remains interested in such issues but does not "have a fully framed position on various financial arrangements" by doctors. "I have two sides to this concern," the Health Care Financing Administration head explained in response to a question by Georgia Pharmaceutical Association Executive VP Larry Braden. "On one side, I can see that there are real conflicts of interest" that can be "harmful to our getting best value for the dollar." "On the other hand," Roper continued, "we are seeking a more competitive health care system, and as competition happens, more and more complicated arrangements are going to be put in place between the various parts of the health care system. What looks very much to one person like a kickback will look to another like a legitimate business relationship." Connecticut Pharmaceutical Association Executive Director Daniel Leone asked whether a physician's override of generic substitution under his state's law, which requires that the prescriber handwrite "no substitution" on the prescription form, satisfies federal Medicaid requirements that the physician write "brand medically necessary." Responding that he would have to consult the federal regulation, Roper maintained that such confusion was the result of policies that dictate rather than let marketplace forces operate. Roper said he supports the idea of prepaid managed care claims "as opposed to further regulating the service system" because otherwise "layer upon layer of bureaucratic detail is inevitable." Roper explained: "The better way is through prepaid managed health care plans . . . so that we can delegate, states can delegate substantial authority, and we don't have to get involved in detailed language" required on an override. Senate Majority Leader Dole (R-Kan.) told the council that long-term health care legislation will be a priority in the next Congress. "I think we had some indication this Congress in the efforts by [Rep.] Claude Pepper [D-Fla.] in the House; he didn't win, but he got a lot of votes for a very, very expensive program." Dole said such a bill "is going to be right on the front burner" because "there is a constituency there, and there is a need."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth